This text is translated into Russian by google automatic human level neural machine.
EastRussia is not responsible for any mistakes in the translated text. Sorry for the inconvinience.
Please refer to the text in Russian as a source.
RDIF agreed to supply Sputnik V to Malaysia
The Russian Direct Investment Fund and the pharmaceutical company Duopharma Sdn Bhd have signed an agreement to supply Sputnik V vaccine to Malaysia. The drug for supply to this country will be produced in China, South Korea and India.
As the TASS With reference to the Russian Ambassador to Malaysia Nail Latypov, the signing ceremony took place in the format of a teleconference. According to him, within the framework of bilateral cooperation, Malaysia will create its own research base for the production of a vaccine against coronavirus.
In Russia, from January 18, began mass vaccination from the coronavirus. Currently, they are vaccinated against COVID-19 with two vaccines - Sputnik V and EpiVacCorona.
The effectiveness of the Sputnik V vaccine against the complex course of COVID-19 amounted to 100%... The overall effectiveness of the drug has exceeded 90%.
The first Russian vaccine against coronavirus Ministry of Health registered in early August 2020. It was developed by the Gamaleya Center.